Treatment with SLS-005 demonstrated a 46% reduction in tau protein and an 18% reduction in NfL biomarker from baseline values within six months Seelos has been selected to present these data at Neuroscience 2023 to be held on November 11-15, 2023 in Washington, D.C....
GLP-1 receptor agonists, primarily approved for type 2 diabetes and obesity, are emerging as potential treatments for other diseases, including Alzheimer’s. Christian Hölscher of Kariya Pharmaceuticals highlighted the hormone’s diverse effects in the body...
There may be no hotter trend in biopharma right now than GLP-1 receptor agonists. Currently approved to treat type 2 diabetes and obesity, this drug class has also shown potential in other indications, from nonalcoholic fatty liver disease and cardiovascular disease...
CRISPR-Cas9—the Nobel Prize–winning gene-editing system developed by Jennifer Doudna and Emmanuelle Charpentier—is on the cusp of breaking into clinical trials for Alzheimer’s disease, but experts note barriers that must be overcome and question whether scientists...
TRIM11 protein levels decreased in Alzheimer’s disease models—new Penn Medicine research suggests replenishing the protein may improve cognitive and motor function Individuals with Alzheimer’s disease (AD) have increased neurofibrillary tangles (NFTs) of tau proteins...
